Johnson & Johnson $JNJ Shares Purchased by AlphaCore Capital LLC

AlphaCore Capital LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 20.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,848 shares of the company’s stock after acquiring an additional 5,343 shares during the quarter. AlphaCore Capital LLC’s holdings in Johnson & Johnson were worth $5,905,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Abich Financial Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at about $26,000. Evolution Wealth Management Inc. acquired a new position in shares of Johnson & Johnson during the second quarter valued at $27,000. Clayton Financial Group LLC acquired a new stake in shares of Johnson & Johnson in the third quarter valued at approximately $28,000. Semmax Financial Advisors Inc. increased its holdings in shares of Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the period. Finally, Compass Financial Services Inc boosted its holdings in shares of Johnson & Johnson by 707.1% in the third quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock valued at $42,000 after acquiring an additional 198 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Strong product momentum: J&J’s oncology franchise (Darzalex) and new data for Tremfya are driving revenue upside and underpinning investor confidence in sustainable growth. Can J&J Sustain Its Double-Digit Oncology Growth Streak?
• Positive Sentiment: FDA filing for a rare-disease drug: J&J submitted an sBLA for IMAAVY (nipocalimab) as a first-ever treatment for wAIHA — approval would add a high-value orphan indication and expand the pipeline. PR Newswire: J&J seeks FDA approval of IMAAVY
• Positive Sentiment: Strategic pivot and MedTech tailwinds: Coverage highlights J&J’s shift into higher-margin medical devices, robotics and Shockwave/IVL tech, supporting margin expansion and a path to ~$100B revenue guidance. Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector
• Positive Sentiment: Potential DePuy Synthes divestiture: Reports that J&J is exploring a major sale of its orthopedics unit could unlock significant cash and simplify the business, a clear value-creation catalyst if executed. J&J Eyes Mega Sale Of DePuy Synthes
• Neutral Sentiment: Analyst moves and valuation tweaks: Street price targets have been nudged modestly higher, but changes are incremental — supportive but not a strong directional signal. How Shifting Analyst Targets Are Rewriting The J&J Investment Story
• Neutral Sentiment: Corporate tech & partnerships story: Reports on J&J’s enterprise tech investments and a first co-funding with Blackstone highlight long-term transformation, but near-term financial impact is unclear. Enterprise Technology Analysis Report
• Negative Sentiment: Bayer lawsuit and legal overhang: Bayer sued over survival-claim marketing for a prostate cancer drug, adding litigation risk and headline volatility for Janssen’s oncology unit. Bayer files lawsuit against J&J
• Negative Sentiment: Insider selling: EVP Timothy Schmid disclosed sales totaling thousands of shares in recent filings — routine but sometimes perceived negatively as profit-taking. SEC Form 4: Timothy Schmid

Insider Activity

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the sale, the executive vice president owned 26,769 shares in the company, valued at $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 30,142 shares of company stock worth $7,360,528 in the last three months. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $245.32 on Thursday. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $247.25. The stock has a 50-day simple moving average of $223.12 and a 200 day simple moving average of $200.79. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $591.19 billion, a price-to-earnings ratio of 22.20, a P/E/G ratio of 2.39 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The company had revenue of $24.28 billion during the quarter. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson’s payout ratio is presently 47.06%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on JNJ. HSBC raised their price objective on shares of Johnson & Johnson from $240.00 to $265.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Royal Bank Of Canada boosted their target price on shares of Johnson & Johnson from $240.00 to $255.00 and gave the company an “outperform” rating in a research note on Tuesday, February 3rd. Wells Fargo & Company upped their price target on shares of Johnson & Johnson from $230.00 to $240.00 and gave the stock an “overweight” rating in a research note on Thursday, January 22nd. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, December 11th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $232.70.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.